A Pathway to Putting Patients First: Spotlight on TAAR1 Agonists for Treating Schizophrenia
Released On
January 29, 2024
Expires On
January 29, 2025
Media Type
Internet
Completion Time
60 minutes
Specialty
Psychiatry
Topic(s)
Schizophrenia
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by Medical Education Resources and CMEology.
This activity is supported by an independent educational grant from Sumitomo Pharma America, Inc. and Otsuka America Pharmaceutical, Inc.
Credit Available
- Physicians — 1.0 AMA PRA Category 1 Credits™
- Nurses — 1.0 Nursing Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed for psychiatrists, advanced practice psychiatric nurses, and other mental health care professionals who care for patients with schizophrenia.
Program Overview
In this activity, two expert faculty members — a psychiatric nurse and a psychiatrist — will give you the opportunity to learn about unmet needs in the management of schizophrenia, including outcomes that are important to patients, the role of psychiatric nurses in schizophrenia care, adverse effects of antipsychotics and their impact on patients’ lives, and the latest clinical data on TAAR1 agonists. Importantly, you will also hear from a patient advocate living with schizophrenia. She will share the daily reality of what living with “unmet needs” and antipsychotic adverse effects looks like, as well as her hope for the future.
Learning Goal/Purpose
The goal of this educational activity is to enhance clinicians’ knowledge of unmet needs in schizophrenia care, familiarize them with the role of psychiatric nurses in improving patient outcomes, and update them on the latest clinical data regarding TAAR1 agonists.
Learning Objectives
After completing this activity, participants should be able to:
- Identify unmet patient needs in the current treatment landscape of schizophrenia
- Appraise the outcomes of adverse effects of conventional antipsychotics, with resulting burden on patients,
healthcare systems and society - Analyze recent and emerging clinical trial data evaluating the efficacy, safety, and tolerability profiles of TAAR1
agonists in the treatment of schizophrenia - Explore potential benefits of emerging therapies on patient-centered outcomes and goals
Faculty
Amber Hoberg, MSN, APRN, PMHNP-BC
Psychiatric Nurse Practitioner
Morning Star Family Medicine PLLC
Baptist Health System
San Antonio, Texas
Eric Achtyes, MD
Professor and Chair
Department of Psychiatry
Western Michigan University
Homer Stryker M.D. School of Medicine
Kalamazoo, Michigan
Bethany Yeiser, BS
Author and Mental Health Advocate
President - CURESZ Foundation
Fairfield, Ohio
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and CMEology. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.
Credit Designation
MER designates this activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Credit Designation
MER designates this activity for a maximum of 1.0 ANCC nursing contact hours. Nurses will be awarded contact hours upon successful completion of the activity.
MER is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.0 contact hours.
Disclosures of Conflicts of Interest
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.
The authors reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:
- Amber Hoberg, MSN, APRN, PMHNP-BC
- Consultant/Advisor: Acadia Pharmaceuticals Inc., Axsome Therapeutics, Inc., BioXcel Therapeutics, Inc., Intra-Cellular Therapies, Inc., Sage Therapeutics and Biogen, Teva Pharmaceuticals.
- Speakers’ Bureau: Acadia Pharmaceuticals Inc., Axsome Therapeutics, Inc., BioXcel Therapeutics, Inc., Intra-Cellular Therapies, Inc., Neurocrine Biosciences, Inc., Otsuka America Pharmaceutical, Inc.
- Consultant/Advisor: Acadia Pharmaceuticals Inc., Axsome Therapeutics, Inc., BioXcel Therapeutics, Inc., Intra-Cellular Therapies, Inc., Sage Therapeutics and Biogen, Teva Pharmaceuticals.
- Eric Achtyes, MD
- Grant/Research Support: Alkermes, Inc., Biogen, Boehringer Ingelheim Pharmaceuticals, Inc., Johnson & Johnson, Karuna Therapeutics, Neurocrine Biosciences, Inc., Takeda Pharmaceuticals North America, Inc., Teva Pharmaceuticals.
- Consultant/Advisor: Alkermes, Inc., Atheneum, Indivior, Karuna Therapeutics, Lundbeck, Inc., Otsuka America Pharmaceutical, Inc.
- Bethany Yeiser, BS
- Grant/Research Support: Karuna Therapeutics
- Consultant: Alkermes, Inc.
Reviewers report the following relationship(s)
CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use/Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
Contact Information
For questions about this activity, please contact CMEology at: [email protected] or Medical Education Resources at: http://cmepartner.org/contact.